Replimune stock.
Indeed, Replimune Group (NASDAQ:REPL) stock is up 152% in the last year, providing strong gains for shareholders. But the harsh reality is that very many loss making companies burn through all ...
A high-level overview of Replimune Group, Inc. (REPL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Replimune Group, Inc. Stock price Equities REPL US76029N1063 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar …Aug 24, 2022 · Billionaires Julian and Felix Baker have been some of the best bio-stock pickers over the past 20 years. ... (CERS-3.09%), and Replimune Group (REPL 0.31%) in the most recent quarter. All three of ... Replimune Group Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.531 per share for the current fiscal year. Replimune Group Inc does not currently pay a dividend.Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.
REPL Stock 12 Months Forecast. $57.33. (396.79% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $57.33 with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 396.79% change from the last price of $11.54. The shares of the biotechnology company that develops oncolytic immune-gene therapies to treat cancer jumped 46% in Wednesday trading, accelerating twelve months gains to 196%. Replimune stock price has been receiving support from the successful results of the Phase 1 clinical trial of RP1 and RP2 in patients with solid tumors.Replimune Group Inc REPL Morningstar Rating Unlock Stock XNAS Rating as of Nov 29, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...
Replimune will have responsibility for operationalizing these clinical trials. ... the Company closed on an offering of common stock and pre-funded warrants raising approximately $259 million in ...
Investors are always looking for stocks that are poised to beat at earnings season and Replimune REPL may be one such company. The firm has earnings coming up pretty soon, and events are shaping ...Shares of Replimune Group Inc. (REPL) surged more than 46% to touch a new high of $46.28 in intraday trading on Wednesday after an analyst at Roth Capital Tony Butler hiked his price target on the ...Find real-time REPL - Replimune Group Inc stock quotes, company profile, news and forecasts from CNN Business.Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ...
At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies.. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...
Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.
Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...Stock Price Forecast The 9 analysts offering 12-month price forecasts for Replimune Group Inc have a median target of 48.00, with a high estimate of 70.00 and a low estimate of 32.00.In conclusion, Replimune Group Inc’s stock performance has been buoyed by positive price forecasts from 10 analysts, with a median target price of $50.00. Despite reporting negative earnings per share for the current quarter, investors remain optimistic about the company’s long-term potential.We would like to show you a description here but the site won’t allow us.Discover historical prices for REPL stock on Yahoo Finance. View daily, weekly or monthly format back to when Replimune Group, Inc. stock was issued.
Nov 24, 2023 · The average price recommended by analysts for Replimune Group Inc is $48.44, which is significantly higher than the current market price. This suggests that there is room for the stock price to increase, according to analysts’ predictions. The company has also been involved in the development of a treatment for cutaneous squamous cell ... Replimune | 9,469 followers on LinkedIn. Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response.Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsOct 15, 2020 · Replimune (NASDAQ: REPL) stock price soared sharply to an all-time high of $46 in Wednesday trading before settling around $36 a share at the end of the session. The shares of the biotechnology company that develops oncolytic immune-gene therapies to treat cancer jumped 46% in Wednesday trading, accelerating twelve months gains to 196%. In conclusion, Replimune Group Inc’s stock performance has been buoyed by positive price forecasts from 10 analysts, with a median target price of $50.00. Despite reporting negative earnings per share for the current quarter, investors remain optimistic about the company’s long-term potential.Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Feb 24, 2023 · Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ...
Historical daily share price chart and data for Replimune since 2018 adjusted for splits and dividends. The latest closing stock price for Replimune as of November 24, 2023 is 10.39.. The all-time high Replimune stock closing price was 52.65 on December 01, 2020.; The Replimune 52-week high stock price is 29.52, which is 184.1% above the current share …
About Replimune Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of …Novartis AG. -0.52%. CHF176.38B. REPL | Complete Replimune Group Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Stock Price. $14.2. 2023-11-03. Market Capitalization. $837.7 M. 2023-11-03. Replimune Summary. Company Summary. Overview. Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens ...WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of Directors effective December 1, 2021. “We are delighted to …Dec 1, 2023 · View Replimune Group, Inc REPL investment & stock information. Get the latest Replimune Group, Inc REPL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Nov 3, 2023 · WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or ... Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune GroupReplimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of ...
Replimune Group Inc REPL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns …
Replimune Group Inc [REPL] stock prices are up 4.74% to $11.71 at the moment. An important factor to consider is whether the stock is rising or falling in short …
Oct 15, 2020 · Shares of Replimune Group ( REPL -2.97%) were soaring 13.3% higher as of 11:01 a.m. EDT on Thursday after rising as much as 22.4% earlier in the day. The big jump resulted from the company's ... Replimune Group Inc (REPL) Stock Price & News - Google Finance Home REPL • NASDAQ Replimune Group Inc Follow Share $10.39 Nov 24, 5:45:00 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.6.68. +0.68. +11.33%. Get Replimune Group Inc (REPL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Replimune Group Stock Performance Shares of REPL stock opened at $11.71 on Monday. The company has a quick ratio of 12.76, a current ratio of 12.76 and a debt-to-equity ratio of 0.11.Nov 5, 2023 · To begin my analysis, Replimune's Q2 earnings revealed an upswing in expenditures, with R&D costs climbing 37% to $40.4M and SG&A expenses up 33% to $15.2M, culminating in a heightened operating ... The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant ...The shares of common stock and the pre-funded warrants described above are being offered by Replimune pursuant to its shelf registration statement on Form S-3, including a base prospectus, that ...
Replimune Group Stock Performance. Shares of NASDAQ REPL opened at $11.71 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 12.76 and a quick ratio of 12.76.Find real-time REPL - Replimune Group Inc stock quotes, company profile, news and forecasts from CNN Business.WOBURN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform ...Instagram:https://instagram. blue jet stockoffice reit etfstock market channelsbiggest gainers in stock market Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients. About Us.Replimune is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. RPx therapies are engineered using a proprietary HSV-1 strain and immune activating transgenes to maximize T cell stimulation and systemic immune activation. RP1 is designed to treat more immune ... trading ideas reviewprediction of silver prices 6.68. +0.68. +11.33%. Get Replimune Group Inc (REPL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. stealth ev WOBURN, Mass. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present. July 31, 2023.Replimune Group, Inc. ( NASDAQ:REPL – Get Free Report) shares were down 3.4% during trading on Friday . The company traded as low as $10.80 and last …